Novartis’ Kymriah fails to hit primary survival endpoint in late-stage trial
The Phase III Belinda study investigating Kymriah (tisagenlecleucel) for treatment of non-Hodgkin lymphoma did not meet its primary endpoint of event-free survival c...
Continue Reading →
